Pfizer and BioNTech officials recently provided an update regarding the Omicron variant, noting results of an initial laboratory study demonstrating serum antibodies via BNT162b2 neutralize the variant after three doses.
“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” Pfizer Chairman and CEO Albert Bourla said. “Ensuring as many people as possible are fully vaccinated with the first two-dose series, and a booster remains the best course of action to prevent the spread of COVID-19.”
The companies indicated sera from vaccines one month after receiving the booster vaccination neutralized the Omicron variant to levels that compare to those observed for the SARS-CoV-2 spike protein after two doses.
“Our preliminary, first data set indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” Dr. Ugur Sahin, CEO and co-founder of BioNTech, said. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season.”
Sahib said work continues regarding an adapted vaccine BioNTech believes would aid in providing heightened protection against Omicron-induced COVID-19 disease.